Julie Refardt

University Hospital Basel
Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Objective Distinguishing arginine vasopressin deficiency (AVP-D; central diabetes insipidus) from primary polydipsia (PP), commonly referred to as psychogenic polydipsia, is challenging. Psychopathologic findings, commonly used for PP diagnosis in clinical practice, are rarely evaluated in AVP-D patients, and no comparative data between the two conditions currently exist. Design Data from two studies involving 82 participants (39 AVP-D, 28 PP, and 15 healthy controls [HC]). Methods Psychological evaluations were conducted using standardized questionnaires measuring anxiety (State-Trait Anxiety-Inventory [STAI]), alexithymia (Toronto Alexithymia-Scale [TAS]), depressive symptoms (Beck’s Depression Inventory-II [BDI-II], and overall mental health (Short-Form-36 Health-Survey [SF-36]). Higher STAI, TAS, and BDI-II scores suggest elevated anxiety, alexithymia, and depression, while higher SF-36 scores signify better overall mental health. Results Compared to HC, patients with AVP-D and PP showed higher levels of anxiety (HC 28 points [24-31] vs AVP-D 36 points [31-45]; vs PP 38 points [33-46], p<0.01), alexithymia (HC 30 points [29-37] vs AVP-D 43 points [35-54]; vs PP 46 points [37-55], p<0.01), and depression (HC 1 point [0-2] vs AVP-D 7 points [4-14]; vs PP 7 points [3-13], p<0.01). Levels of anxiety, alexithymia, and depression showed no difference between both patient groups (p=0.58, p=0.90, p=0.50, respectively). Compared to HC, patients with AVP-D and PP reported similarly reduced self-reported overall mental health scores (HC 84 [68-88] vs AVP-D 60 [52-80], p=0.05; vs PP 60 [47-74], p<0.01). Conclusion This study reveals heightened anxiety, alexithymia, depression, and diminished overall mental health in patients with AVP-D and PP. The results emphasize the need for careful interpretation of psychopathological characteristics to differentiate between AVP-D and PP.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (9)

Lukas Sommer

Professor

University of Zurich

SWITZERLAND
View details

Wouter de Herder

Professor of Endocrine Oncology

Erasmus University Rotterdam

NETHERLANDS
View details

Damian Wild

Head of Nuclear Medicine

University Hospital Basel

SWITZERLAND
View details

Bettina Winzeler

-

SWITZERLAND
View details

Emanuel Christ

University Hospital Basel

SWITZERLAND
View details

Himeka Hayashi

Okayama University

JAPAN
View details

Leo Hofland

Erasmus University Rotterdam

NETHERLANDS
View details

Mirjam Christ-Crain

University Hospital Basel

SWITZERLAND
View details

Volker Burst

-

GERMANY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.